Riparian Pharmaceuticals, (a Viva Biotech portfolio company), a biotechnology company focused on discovering novel therapeutics for cardiovascular diseases, entered into an exclusive license agreement and research agreement with Pfizer. In exchange for exclusive rights to a Riparian preclinical program, Pfizer will make upfront and milestone payments, as well as pay royalties on sales of resulting therapeutics. As part of the research agreement, Pfizer will support Riparian’s efforts to...